Kristen Galfetti is a Vice President of Investor Relations and Corporate Communications at Cynapsus Therapeutics Inc. Ms. Galfetti has over 20 years of experience in investor relations and corporate communications. She has held key roles developing communications programs for small and large health care companies. Ms. Galfetti’s recent corporate experience includes serving as Senior Director, Investor Relations at Sanofi, responsible for integrating the Genzyme Corporation investor relations program post-merger. Prior to Sanofi, Ms. Galfetti was Senior Director of Corporate Communications and Investor Relations at AMAG Pharmaceuticals, where she created the dual functioning department. Ms. Galfetti held roles of increasing responsibility at Genzyme Corporation, serving most recently as Senior Director, Investor Relations, assisting with integrating the tracking stock structure communications into a single business story. Ms. Galfetti received her MBA — with distinction — from Bentley University and a B.A. in political science from the University of Vermont.
